XPH:NYE-SPDR® S&P Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 47.29

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-20 )

ETFs Containing XPH

INAV 10.31 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -43.19% 43% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -43.19% 43% F 15% F
Trailing 12 Months  
Capital Gain -35.61% 43% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.61% 43% F 15% F
Trailing 5 Years  
Capital Gain -36.83% 33% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -36.83% 33% F 24% F
Average Annual (5 Year Horizon)  
Capital Gain -0.63% 14% F 31% F
Dividend Return 0.07% 19% F 23% F
Total Return 0.69% 68% D+ 16% F
Risk Return Profile  
Volatility (Standard Deviation) 15.54% 62% D 64% D
Risk Adjusted Return 0.42% 19% F 23% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.